Cargando…
MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia
Activation of p53 by small molecule MDM2 inhibitors can induce cell cycle arrest or death in p53 wildtype cancer cells. However, cancer cells exposed to hypoxia can develop resistance to other small molecules, such as chemotherapies, that activate p53. Here, we evaluated whether hypoxia could render...
Autores principales: | Lerma Clavero, Ada, Boqvist, Paula Lafqvist, Ingelshed, Katrine, Bosdotter, Cecilia, Sedimbi, Saikiran, Jiang, Long, Wermeling, Fredrik, Vojtesek, Borivoj, Lane, David P., Kannan, Pavitra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027891/ https://www.ncbi.nlm.nih.gov/pubmed/36941277 http://dx.doi.org/10.1038/s41598-023-31484-0 |
Ejemplares similares
-
The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
por: Ingelshed, Katrine, et al.
Publicado: (2022) -
CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
por: Jiang, Long, et al.
Publicado: (2022) -
The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276
por: Li, Ruidong, et al.
Publicado: (2020) -
Rearrangement of mitochondrial pyruvate dehydrogenase subunit dihydrolipoamide dehydrogenase protein–protein interactions by the MDM2 ligand nutlin‐3
por: Way, Luke, et al.
Publicado: (2016) -
Structure of a Stapled Peptide Antagonist Bound to Nutlin-Resistant Mdm2
por: Chee, Sharon Min Qi, et al.
Publicado: (2014)